A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.

@article{Welte1996ARP,
  title={A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-M{\"u}nster Study Group.},
  author={Karl Welte and A. Reiter and Kerstin Mempel and Marina Pfetsch and Gisela G. Schwab and Martin Schrappe and Hansjorg Riehm},
  journal={Blood},
  year={1996},
  volume={87 8},
  pages={3143-50}
}
Overall chemotherapeutic treatment results in pediatric acute lymphoblastic leukemia (ALL) are good, with event-free survival (EFS) rates over 70%. However, for a subset of patients characterized by high-risk (HR) features the outcome is less favorable, with EFS rates below 50%. Intensification of chemotherapy may improve the outcome for those patients, but increased toxicity, particularly myelosuppression, limits the escalation of dose intensity. Recombinant methionyl human granulocyte colony… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…